Cormorant Asset Management, LP Akero Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $4.24 Million - $6.54 Million	115,000 New	115,000 $5.37 Million
Q4 2021 Feb 14, 2022	SELL	$19.87 - $26.24 $3.9 Million - $5.15 Million	-196,213 Reduced 32.7%	403,787 $8.54 Million
Q2 2021 Aug 16, 2021	SELL	$24.81 - $32.35 $3.54 Million - $4.61 Million	-142,549 Reduced 19.2%	600,000 $14.9 Million
Q4 2020 Feb 16, 2021	SELL	$25.12 - $29.89 $2.94 Million - $3.5 Million	-117,001 Reduced 13.61%	742,549 $19.2 Million
Q3 2020 Nov 16, 2020	BUY	$30.79 - $39.92 $8.22 Million - $10.7 Million	267,011 Added 45.06%	859,550 $26.5 Million
Q2 2020 Aug 14, 2020	SELL	$19.25 - $26.76 $962,500 - $1.34 Million	-50,000 Reduced 7.78%	592,539 $14.8 Million
Q1 2020 May 15, 2020	SELL	$12.8 - $27.05 $1.26 Million - $2.65 Million	-98,082 Reduced 13.24%	642,539 $13.6 Million
Q3 2019 Nov 14, 2019	SELL	$16.89 - $29.88 $459,762 - $813,363	-27,221 Reduced 3.55%	740,621 $16.8 Million
Q2 2019 Aug 14, 2019	BUY	$18.08 - $19.83 $13.9 Million - $15.2 Million	767,842 New	767,842 $14.7 Million

190

74.4M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.11B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.